GlassScriptPhysician profile
Lawrence William Elmer
NPI 1043206196
$686,783.98
in general payments reported to CMS, 2019-2025
24 companies · $134K in 2025
The $134K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $38K · 2021: $94K · 2022: $139K · 2023: $138K · 2024: $89K · 2025: $134K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $244K · Consulting Fee: $77K · Travel and Lodging: $25K · Food and Beverage: $14K · Education: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $243,948.05 |
| Consulting Fee | $76,857.50 |
| Travel and Lodging | $24,871.73 |
| Food and Beverage | $14,171.95 |
| Education | $868.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $182,368.33 | 2020-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $175,316.49 | 2019-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $154,714.44 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Kyowa Kirin, INC. | $88,555.13 | 2020-2023 | Nourianz |
| Amneal Pharmaceuticals LLC | $52,575.17 | 2019-2025 | Ongentys, Crexont |
| Acorda Therapeutics, INC | $22,079.53 | 2019-2021 | |
| Mdd US Operations, LLC | $5,742.58 | 2022 | |
| Sunovion Pharmaceuticals INC. | $2,632.20 | 2020-2021 | |
| Medtronic, INC. | $1,061.06 | 2021-2022 | |
| Ucb, INC. | $929.97 | 2019-2024 | Briviact |
| Abbvie INC. | $576.77 | 2019-2025 | |
| Pyros Pharmaceuticals, INC. | $43.28 | 2024 | Vigpoder |
| Alexion Pharmaceuticals, INC. | $41.66 | 2019-2021 | |
| Pfizer INC. | $34.61 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $25.12 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saol Therapeutics INC. | $16.83 | 2019 | |
| Sk Life Science, INC. | $15.62 | 2021 | |
| Aquestive Therapeutics, INC. | $15.00 | 2019 | |
| Adamas Pharmaceuticals, INC. | $14.30 | 2019 | |
| Lundbeck LLC | $14.00 | 2022 | |
| Neurelis, INC. | $11.89 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Elmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.